Latest Strategic Investment News

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Smartpay has reported an 8.5% rise in consolidated revenue for FY2025, driven by growth in Australia and a bold entry into New Zealand’s acquiring market. However, investments in technology and market expansion have weighed on EBITDA.

Strickland Metals reports robust diamond drilling results at its Gradina Prospect, extending high-grade gold mineralisation and setting the stage for a maiden resource estimate in late 2025.

Straker Ltd reports a solid FY25 performance marked by a strategic shift from legacy translation services to AI-powered language verification, underpinned by robust cash reserves and improved profitability.

Viva Leisure has taken a strategic 33% stake in Gorilla X Labs, aiming to deepen its footprint in the sports nutrition market and enhance member offerings across its platforms.

Turners Automotive Group has delivered a record FY25 profit and dividend, showcasing resilience amid economic challenges and positioning itself to exceed FY28 profit goals ahead of schedule.

Restaurant Brands posted a record $1.4 billion in sales for FY24, alongside a 62.6% surge in net profit, despite ongoing inflation and economic uncertainty. The company remains cautious on FY25 guidance but is focused on margin improvement and strategic growth.

Lion Selection Group has committed $1 million to Koonenberry Gold’s $5 million placement, increasing its stake to nearly 7% following promising gold discoveries at the Enmore project.

Raiden Resources has increased its ownership in the Vuzel Gold Project from 51% to 75%, marking a key milestone driven by promising near-surface and high-grade gold discoveries. The company eyes further ownership gains as drilling continues.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

Aerometrex’s flagship platform MetroMap has reached a significant milestone, surpassing $10 million in Annual Contract Value, reflecting strong growth and customer trust since its 2020 launch.